About Me
Strategic life sciences leader with 25+ years of experience shaping product and portfolio strategy across early- and late-stage assets. Proven success in translating scientific innovation into global commercial strategy, with deep experience across multiple therapy areas, including oncology, respiratory, immunology, cardiovascular, plus biosimilars, cell/gene therapies and rare diseases. Expertise in early asset evaluation, indication prioritization, and cross-functional portfolio planning that aligns R&D, medical, and commercial objectives.
Education
University of Kent 1999
PhD Microbiology
BBSRC/CASE Studentship titled “Biotransformation of acyclic monoterpene alcohols: the search for biocatalytic routes to aromatic cyclic ethers.” Included industrial sponsorship (Zylepsis Limited).
University of Surrey 1995
BSc(Hons) Biochemistry (Medical)
Included an industrial placement within the Drug Metabolism and Pharmacokinetics unit of Upjohn Laboratories Europe where I developed a method of studying the metabolism of pipeline assets using liver slice technology.